Robert J.  Polzer net worth and biography

Robert Polzer Biography and Net Worth

EVP of Zoetis

Robert J. Polzer, Ph.D., is Executive Vice President and President, Research and Development at Zoetis, the world’s leading animal health company and a member of the Fortune 500. In this role, he is responsible for leading a global organization that discovers, develops and registers new products, including genetic testing, vaccines, diagnostics and therapeutics that help predict, prevent, detect and treat animal health conditions in the eight core species that Zoetis serves. He also leads teams that develop new sensor and biodevice instruments to complement the core portfolio.

Dr. Polzer joined Zoetis in 2015 as the Head of Global Therapeutics where he led research and development activities to discover and register innovative solutions. He has been pivotal in advancing the company’s recent innovations, including monoclonal antibody platforms across species and therapeutic areas and a growing portfolio of companion animal parasiticides. He has also fostered external innovation collaborations with Colorado State University, which is involved in identifying new companion animal allergy and dermatology solutions and developing new immunotherapies that could pave the way for alternatives to antibiotics in food-producing animals, as well as with Regeneron to explore the connections between animal and human health.

What is Robert J. Polzer's net worth?

The estimated net worth of Robert J. Polzer is at least $416,433.94 as of August 9th, 2023. Dr. Polzer owns 2,353 shares of Zoetis stock worth more than $416,434 as of November 23rd. This net worth evaluation does not reflect any other assets that Dr. Polzer may own. Additionally, Dr. Polzer receives a salary of $1,180,000.00 as EVP at Zoetis. Learn More about Robert J. Polzer's net worth.

How old is Robert J. Polzer?

Dr. Polzer is currently 55 years old. There are 7 older executives and no younger executives at Zoetis. The oldest executive at Zoetis is Ms. Roxanne Lagano, EVP, Chief HR Officer & Global Operations, Interim General Counsel and Corporate Secretary, who is 59 years old. Learn More on Robert J. Polzer's age.

What is Robert J. Polzer's salary?

As the EVP of Zoetis Inc., Dr. Polzer earns $1,180,000.00 per year. There are 4 executives that earn more than Dr. Polzer. The highest earning executive at Zoetis is Ms. Kristin C. Peck, CEO & Director, who commands a salary of $3,540,000.00 per year. Learn More on Robert J. Polzer's salary.

How do I contact Robert J. Polzer?

The corporate mailing address for Dr. Polzer and other Zoetis executives is 10 Sylvan Way, Parsippany NJ, 07054. Zoetis can also be reached via phone at (973) 822-7000 and via email at [email protected]. Learn More on Robert J. Polzer's contact information.

Has Robert J. Polzer been buying or selling shares of Zoetis?

Robert J. Polzer has not been actively trading shares of Zoetis during the last quarter. Most recently, Robert J. Polzer sold 1,179 shares of the business's stock in a transaction on Wednesday, August 9th. The shares were sold at an average price of $189.94, for a transaction totalling $223,939.26. Following the completion of the sale, the executive vice president now directly owns 2,353 shares of the company's stock, valued at $446,928.82. Learn More on Robert J. Polzer's trading history.

Who are Zoetis' active insiders?

Zoetis' insider roster includes Juan Alaix (Director), Heidi Chen (EVP), Glenn David (EVP), Andrew Fenton (EVP), Wetteny Joseph (Exec. VP & CFO ), Robert Kelly (EVP), Catherine Knupp (EVP), Roxanne Lagano (EVP), Clinton Lewis, Jr. (EVP), Gregory Norden (Director), Kristin Peck (CEO), Robert Polzer (EVP), Willie Reed (Director), Linda Rhodes (Director), Robert Scully (Director), and Roman Trawicki (EVP). Learn More on Zoetis' active insiders.

Are insiders buying or selling shares of Zoetis?

In the last twelve months, insiders at the sold shares 5 times. They sold a total of 5,632 shares worth more than $1,047,983.01. The most recent insider tranaction occured on April, 18th when EVP Roxanne Lagano sold 923 shares worth more than $139,529.91. Insiders at Zoetis own 0.2% of the company. Learn More about insider trades at Zoetis.

Information on this page was last updated on 4/18/2024.

Robert J. Polzer Insider Trading History at Zoetis

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/9/2023Sell1,179$189.94$223,939.262,353View SEC Filing Icon  
See Full Table

Robert J. Polzer Buying and Selling Activity at Zoetis

This chart shows Robert J Polzer's buying and selling at Zoetis by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Zoetis Company Overview

Zoetis logo
Zoetis Inc. engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses. It also offers parasiticides, vaccines, dermatology, other pharmaceutical, anti-infectives, animal health diagnostics, and medicated feed additives. In addition, the company provides animal health diagnostics, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, which include nutritionals, as well as products and services in biodevices, genetic tests, and precision animal health. It markets its products to veterinarians, livestock producers, and pet owners. The company has collaboration Blacksmith Medicines, Inc. to discover and develop novel antibiotics for animal health. Zoetis Inc. was founded in 1952 and is headquartered in Parsippany, New Jersey.
Read More

Today's Range

Now: $176.98
Low: $176.00
High: $178.07

50 Day Range

MA: $185.62
Low: $170.37
High: $196.48

2 Week Range

Now: $176.98
Low: $144.80
High: $201.92

Volume

1,854,572 shs

Average Volume

2,542,333 shs

Market Capitalization

$79.85 billion

P/E Ratio

33.27

Dividend Yield

0.98%

Beta

0.9